Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma

Reda S. Saad, Krista L. Denning, Sydney D. Finkelstein, Yulin Liu, Telma C. Pereira, Xiaoqi Lin, Jan F. Silverman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Histologic criteria have a limited role in determining whether the synchronous bilateral breast carcinomas represent two primaries or a metastasis to the contralateral breast. We studied the molecular analysis of synchronous bilateral breast carcinoma and whether they are originating from a single or different clone. We examined 17 patients with breast carcinoma, including 12 patients with synchronous bilateral carcinomas and control group of 5 infiltrating ductal carcinomas with regional lymph node metastases. Mutations were quantitatively determined to detect loss of heterozygosity (LOH) and microsatellite size alterations for a broad panel of 15 markers, involving 10 chromosomes using polymerase chain reaction. The carcinomas were classified as de novo or metastasis based on three levels of concordance: (1) marker-affected tumors were considered concordant if 50% or more of the same markers were mutated, (2) same gene copy affected, and (3) temporal sequence of mutation acquisition. In synchronous bilateral breast carcinoma patients, molecular analysis showed discordant mutations in all cases, supporting the diagnosis of de novo bilateral primary breast carcinomas. In patients with lymph node metastases, the primary breast carcinoma and metastases shared the same mutations, revealing a metastatic lesion. In conclusion, the application of molecular technology may play an important role for the differential diagnosis of dual primary carcinomas vs a metastatic breast cancer to contralateral breast. In this study, synchronous bilateral breast cancers represent two independent primaries rather than metastatic events.

Original languageEnglish (US)
Pages (from-to)1200-1207
Number of pages8
JournalModern Pathology
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Mutation
Carcinoma
Breast
Lymph Nodes
Chromosomes, Human, Pair 10
Ductal Carcinoma
Loss of Heterozygosity
Tumor Biomarkers
Microsatellite Repeats
Differential Diagnosis
Clone Cells
Technology
Polymerase Chain Reaction
Control Groups
Genes

Keywords

  • LOH
  • Molecular pathology
  • Synchronous bilateral breast carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Saad, R. S., Denning, K. L., Finkelstein, S. D., Liu, Y., Pereira, T. C., Lin, X., & Silverman, J. F. (2008). Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Modern Pathology, 21(10), 1200-1207. https://doi.org/10.1038/modpathol.2008.35
Saad, Reda S. ; Denning, Krista L. ; Finkelstein, Sydney D. ; Liu, Yulin ; Pereira, Telma C. ; Lin, Xiaoqi ; Silverman, Jan F. / Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. In: Modern Pathology. 2008 ; Vol. 21, No. 10. pp. 1200-1207.
@article{2bcb54a0413d437f81a7ad44116fee9c,
title = "Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma",
abstract = "Histologic criteria have a limited role in determining whether the synchronous bilateral breast carcinomas represent two primaries or a metastasis to the contralateral breast. We studied the molecular analysis of synchronous bilateral breast carcinoma and whether they are originating from a single or different clone. We examined 17 patients with breast carcinoma, including 12 patients with synchronous bilateral carcinomas and control group of 5 infiltrating ductal carcinomas with regional lymph node metastases. Mutations were quantitatively determined to detect loss of heterozygosity (LOH) and microsatellite size alterations for a broad panel of 15 markers, involving 10 chromosomes using polymerase chain reaction. The carcinomas were classified as de novo or metastasis based on three levels of concordance: (1) marker-affected tumors were considered concordant if 50{\%} or more of the same markers were mutated, (2) same gene copy affected, and (3) temporal sequence of mutation acquisition. In synchronous bilateral breast carcinoma patients, molecular analysis showed discordant mutations in all cases, supporting the diagnosis of de novo bilateral primary breast carcinomas. In patients with lymph node metastases, the primary breast carcinoma and metastases shared the same mutations, revealing a metastatic lesion. In conclusion, the application of molecular technology may play an important role for the differential diagnosis of dual primary carcinomas vs a metastatic breast cancer to contralateral breast. In this study, synchronous bilateral breast cancers represent two independent primaries rather than metastatic events.",
keywords = "LOH, Molecular pathology, Synchronous bilateral breast carcinoma",
author = "Saad, {Reda S.} and Denning, {Krista L.} and Finkelstein, {Sydney D.} and Yulin Liu and Pereira, {Telma C.} and Xiaoqi Lin and Silverman, {Jan F.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1038/modpathol.2008.35",
language = "English (US)",
volume = "21",
pages = "1200--1207",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

Saad, RS, Denning, KL, Finkelstein, SD, Liu, Y, Pereira, TC, Lin, X & Silverman, JF 2008, 'Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma', Modern Pathology, vol. 21, no. 10, pp. 1200-1207. https://doi.org/10.1038/modpathol.2008.35

Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. / Saad, Reda S.; Denning, Krista L.; Finkelstein, Sydney D.; Liu, Yulin; Pereira, Telma C.; Lin, Xiaoqi; Silverman, Jan F.

In: Modern Pathology, Vol. 21, No. 10, 01.10.2008, p. 1200-1207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma

AU - Saad, Reda S.

AU - Denning, Krista L.

AU - Finkelstein, Sydney D.

AU - Liu, Yulin

AU - Pereira, Telma C.

AU - Lin, Xiaoqi

AU - Silverman, Jan F.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Histologic criteria have a limited role in determining whether the synchronous bilateral breast carcinomas represent two primaries or a metastasis to the contralateral breast. We studied the molecular analysis of synchronous bilateral breast carcinoma and whether they are originating from a single or different clone. We examined 17 patients with breast carcinoma, including 12 patients with synchronous bilateral carcinomas and control group of 5 infiltrating ductal carcinomas with regional lymph node metastases. Mutations were quantitatively determined to detect loss of heterozygosity (LOH) and microsatellite size alterations for a broad panel of 15 markers, involving 10 chromosomes using polymerase chain reaction. The carcinomas were classified as de novo or metastasis based on three levels of concordance: (1) marker-affected tumors were considered concordant if 50% or more of the same markers were mutated, (2) same gene copy affected, and (3) temporal sequence of mutation acquisition. In synchronous bilateral breast carcinoma patients, molecular analysis showed discordant mutations in all cases, supporting the diagnosis of de novo bilateral primary breast carcinomas. In patients with lymph node metastases, the primary breast carcinoma and metastases shared the same mutations, revealing a metastatic lesion. In conclusion, the application of molecular technology may play an important role for the differential diagnosis of dual primary carcinomas vs a metastatic breast cancer to contralateral breast. In this study, synchronous bilateral breast cancers represent two independent primaries rather than metastatic events.

AB - Histologic criteria have a limited role in determining whether the synchronous bilateral breast carcinomas represent two primaries or a metastasis to the contralateral breast. We studied the molecular analysis of synchronous bilateral breast carcinoma and whether they are originating from a single or different clone. We examined 17 patients with breast carcinoma, including 12 patients with synchronous bilateral carcinomas and control group of 5 infiltrating ductal carcinomas with regional lymph node metastases. Mutations were quantitatively determined to detect loss of heterozygosity (LOH) and microsatellite size alterations for a broad panel of 15 markers, involving 10 chromosomes using polymerase chain reaction. The carcinomas were classified as de novo or metastasis based on three levels of concordance: (1) marker-affected tumors were considered concordant if 50% or more of the same markers were mutated, (2) same gene copy affected, and (3) temporal sequence of mutation acquisition. In synchronous bilateral breast carcinoma patients, molecular analysis showed discordant mutations in all cases, supporting the diagnosis of de novo bilateral primary breast carcinomas. In patients with lymph node metastases, the primary breast carcinoma and metastases shared the same mutations, revealing a metastatic lesion. In conclusion, the application of molecular technology may play an important role for the differential diagnosis of dual primary carcinomas vs a metastatic breast cancer to contralateral breast. In this study, synchronous bilateral breast cancers represent two independent primaries rather than metastatic events.

KW - LOH

KW - Molecular pathology

KW - Synchronous bilateral breast carcinoma

UR - http://www.scopus.com/inward/record.url?scp=52549084298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52549084298&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2008.35

DO - 10.1038/modpathol.2008.35

M3 - Article

C2 - 18469799

AN - SCOPUS:52549084298

VL - 21

SP - 1200

EP - 1207

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -